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Factor Xa Induces Cytokine Production and Expression of
Adhesion Molecules by Human Umbilical Vein Endothelial
Cells
Nicole H. M. Senden,1* Trudi M. A. A. Jeunhomme,* Johan W. M. Heemskerk,†‡
Rob Wagenvoord,† Cornelis van’t Veer,2* H. Coenraad Hemker,† and Wim A. Buurman*
Proinflammatory effects induced by the serine protease factor Xa were investigated in HUVEC. Exposure of cells to factor Xa
(5–80 nM) concentration dependently stimulated the production of IL-6, IL-8, and monocyte chemotactic protein-1 (MCP-1) and
the expression of E-selectin, ICAM-1, and VCAM-1, which was accompanied by polymorphonuclear leukocyte adhesion. The
effects of factor Xa were blocked by antithrombin III, but not by the thrombin-specific inhibitor hirudin, suggesting that factor
Xa elicits these responses directly and not via thrombin. IL-1a and TNF-a were not implicated, since neither the IL-1 receptor
antagonist nor a TNF-neutralizing Ab could suppress the factor Xa responses. Active site-inhibited factor Xa and factor Xa
depleted from g-carboxyglutamic acid residues were completely inactive. The effector cell protease receptor-1 (EPR-1) seems not
to be involved since anti-EPR-1 Abs failed to inhibit cytokine production. Moreover, neither the factor X peptide Leu83-Leu88,
representing the inter-epidermal growth factor sequence in factor Xa that mediates ligand binding to EPR-1, nor the peptide AG1,
corresponding to the EPR-1 sequence Ser123-Pro137 implicated in factor Xa binding, inhibited the factor Xa-induced cytokine
production. In conclusion, these findings indicate that factor Xa evokes a proinflammatory response in endothelial cells, which
requires both its catalytic and g-carboxyglutamic acid-containing domain. The receptor system involved in these responses in-
duced by factor Xa remains to be established. The Journal of Immunology, 1998, 161: 4318–4324.
T he serine protease factor Xa plays a central role in thecoagulation cascade, linking the extrinsic and intrinsicpathways by catalyzing the conversion of prothrombin to
thrombin on vascular cell surfaces (1). Once generated, factor Xa
forms the Ca21- and phospholipid-dependent prothrombinase
complex with cofactor V/Va on activated platelets, monocytes, or
endothelial cells (2, 3). In addition, factor Xa has been shown to
mediate a variety of other biologic effects such as stimulation of
lymphocyte proliferation in the presence of accessory mediators
(4) and induction of mitogenesis of endothelial and smooth muscle
cells (5–7). In a recent study, factor Xa has also been found to
trigger acute inflammatory responses in vivo (8). Many of these
cellular responses are reported to be mediated through the binding
of factor Xa with the specific membrane receptor effector cell pro-
tease receptor-1 (EPR-1)3 (5, 9, 10).
It has been well established that the inflammatory and coagula-
tion pathways are invariably linked. Various serine proteases trig-
ger a diversity of proinflammatory responses, in addition to their
critical role in coagulation and fibrinolytic processes. For instance,
thrombin and urokinase interact with specific receptors and elicit
typical inflammatory responses, characterized by leukocyte migra-
tion and chemotaxis as well as adhesion to endothelium (11–15).
Since factor Xa may also function as a mediator of inflammation,
we aimed to search for potential proinflammatory effects of factor
Xa on endothelial cells. To this end, we determined the capability
of factor Xa to induce the production of the cytokines IL-6, IL-8,
and monocyte chemotactic protein-1 (MCP-1), as well as the sur-
face expression of the cell adhesion molecules E-selectin,
ICAM-1, and VCAM-1, by HUVEC. In addition, we examined the
structural requirements of factor Xa necessary for endothelial cell
activation. Since a few studies have underscored the involvement
of EPR-1 in the action of factor Xa on several cell types, we in-
vestigated its participation in the factor Xa-induced proinflamma-
tory responses on endothelial cells.
Materials and Methods
Materials
Human thrombin (3120 NIH U/mg protein), heparin, FMLP, and LPS
(from Escherichia coli serotype 055:B5) were all obtained from Sigma (St.
Louis, MO). Hirudin and human rTNF-a were provided by BASF/Knoll
(Ludwigshafen, Germany). Recombinant IL-1a and the IL-1 receptor an-
tagonist (IL-1Ra) were kind gifts, respectively, of Dr. Gillis (Immunex,
Seattle, WA) and Dr. Vannice (Amgen, Boulder, CO). Factor Xa substrate
(Pefachrome Xa) was obtained from Pentapharm (Basel, Switzerland), and
thrombin-cleavable substrate (S2238) from KabiVitrum (Stockholm, Swe-
den). Factor X was purified from bovine and human plasma as described
(16) and activated with Russell’s viper venom according to the method of
Fujikawa et al. (17). Factor Xa activity was measured by the ability to
hydrolyse Pefachrome Xa. Purity was controlled by SDS-PAGE and stain-
ing with Coomassie brilliant blue. Modified factor Xa, lacking the g-car-
boxyglutamic acid (gla) residues (factor Xa-gla), was a kind gift from Drs.
J. Rosing and G. Tans (Department of Biochemistry, University of Maas-
tricht) and was prepared as described by Morita and Jackson (18). The
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concentration of factor Xa-gla was calculated from its activity toward Pe-
fachrome Xa, assuming identical amidolytic activity as factor Xa. Active
site-inhibited factor Xa was obtained by incubation of native factor Xa with
dansyl-glutamylglycyl-L-arginine (DEGR) chloromethyl ketone (Calbio-
chem, La Jolla, CA), as described previously (19). Antithrombin III
(ATIII) was obtained from bovine plasma and purified to homogeneity
according to the method of Thaler et al. (20). Incubation of factor Xa with
equimolar ATIII resulted in complete loss of factor Xa coagulant activity.
Factor Xa and ATIII were tested for LPS activity by the Limulus amebo-
cyte lysate assay according to the manufacturer’s instructions (Endosafe,
Charleston, SC) and were found to contain ,10 pg/ml LPS.
The anti-EPR-1 mAbs 9D4 and B6, shown to bind to the EPR-1 se-
quence Pro120-Ala154, representing the factor Xa-binding site on EPR-1,
the factor X peptide Leu83-Phe84-Thr85-Arg86-Lys87-Leu88-(Gly), representing
the interconnecting epidermal growth factor sequence in factor Xa, which me-
diates ligand binding to EPR-1, and its control scrambled variant Lys-Phe-
Thr-(Gly)-Arg-Leu-Leu were kindly provided by Dr. D. C. Altieri (Depart-
ment of Pathology, Yale University School of Medicine, New Haven, CT) (21,
22). The partially overlapping peptides S123PGKPGNQNSKNEPP137 (AG1)
and P136 PKKRERERSSHCYP150 (AG2), corresponding to the sequences of
EPR-1 implicated in interaction with factor Xa (21), were synthesized by Dr.
J. W. Drijfhout (Department of Immunohematology, Academic Hospital, Lei-
den, The Netherlands). Control mAb CB1, produced by the cell line MOPC21,
was obtained from Celltech (Berkshire, U.K.). Fibronectin was kindly pro-
vided by Dr. J. van Mourik (CLB, Amsterdam, The Netherlands). RPMI 1640
and human endothelial serum-free medium with L-glutamine were obtained
from Life Technologies (Paisley, U.K.); endothelial cell growth supplement
was purchased from Becton Dickinson (Bedford, MA); and bovine calf serum
was obtained from HyClone (Logan, UT). Human serum, obtained after in-
formed consent from healthy donors at the Red Cross Blood Bank Zuid Lim-
burg (Maastricht, The Netherlands), was pooled and sterilized by filtration
through an 0.22-mm pore size filter (Millipore, Bedford, MA). The serum was
heated at 56°C for 30 min before storage at 4°C.
Cell culturing and stimulation procedures
HUVEC were isolated from fresh umbilical cords by treatment with col-
lagenase type I (Sigma) and were seeded into fibronectin-coated tissue
culture flasks (Costar, Cambridge, MA) in RPMI 1640 supplemented with
10% human serum, 10% bovine calf serum, 50 g/ml heparin, 30 g/ml
endothelial cell growth supplement, 2 mM L-glutamine, and antibiotics. For
stimulation experiments, endothelial cells of passages 1 through 4 were
trypsinized, seeded at a density of 104 cells/well, and cultured for 2 to 3
days to confluence in fibronectin-coated 96-well flat-bottom tissue culture
plates in air containing 5% CO2 at 37°C. Before stimulation, the cells were
washed extensively and placed in serum-free culture medium. Stimulation
of the cells was initiated by adding 100 ml of fresh serum-free medium
containing the test reagents. In experiments designed to test inhibition of
factor Xa, Xa was preincubated with the inhibitors for 40 min before it was
added to the cells. In the experiments to elucidate the possible intermediate
role of IL-1a or TNF-a, IL-1Ra or TNF-neutralizing mAb 61E71 (23)
were added simultaneously with factor Xa, IL-1a, or TNF-a to the cells.
For studies to investigate EPR-1 involvement cells were, respectively, pre-
incubated for 30 min and 1 h, with increasing concentrations (0.25–1 mM)
of the factor X-derived peptide Leu83-Leu88 and its scrambled control or
with various dilutions (25–100 mg/ml) of the anti-EPR-1 mAbs 9D4 and
B6 or the control mAb CB1, before addition of factor Xa (5–40 nM) to the
cells. In addition, for peptide competition experiments with the peptides
AG1 and AG2, factor Xa was preincubated with increasing concentrations
(0.25–1 mM) of these peptides for 15 min before addition to HUVEC
monolayers. Culture supernatants were harvested at the end of the incu-
bation period and stored at 220°C until use for determination of cytokine
levels by ELISA. The cells were fixed for determination of adhesion mol-
ecule expression.
Normal human polymorphonuclear leukocytes (PMNs) were isolated
from freshly drawn heparin-anticoagulated blood from healthy donors by
means of Lymphoprep (Nycomed, Oslo, Norway) gradient centrifugation,
followed by lysis of the contaminating erythrocytes in an isotonic ammo-
nium chloride solution (24). PMNs were then resuspended in RPMI 1640
supplemented with 0.1% BSA and stimulated with 1 mM FMLP before
addition to HUVEC for the adhesion assay.
Cytokine assays
Cytokine levels in culture supernatants were determined using a previously
described sandwich ELISA for IL-6 (25) and a newly developed ELISA for
IL-8. ImmunoMaxisorp plates (Nunc, Roskilde, Denmark) were coated
overnight at 4°C with murine anti-IL-6 mAb 5E1 or a newly generated
IL-8-specific murine mAb (IgG1), designated HM-7. Human rIL-6, kindly
provided by Dr. W. Sebald (Physiologisch-Chemisches Institut der Uni-
versita¨t, Wu¨rzburg, Germany), and human rIL-8, kindly provided by Dr. I.
Lindley (Novartis Forschungs Institute, Vienna, Austria), were used for
standard titration curves. Samples were tested in quadruplicate, diluted in
0.1% (w/v) BSA in PBS, and incubated for 2 h at room temperature. Bi-
otinylated polyclonal rabbit Ig to human IL-6 or IL-8 were incubated at
room temperature for 1 h, followed by five washings in 0.1% (w/v) Tween
20 in distilled water and a 1-h incubation with peroxidase-labeled strepta-
vidin (Zymed, San Francisco, CA). Peroxidase activity was determined by
addition of the substrate tetramethylbenzidine. The reaction was stopped
after 15 min with 1 M H2SO4, and quantitation was performed by photo-
spectrometry at 450 nm. MCP-1 concentrations were determined using a
human MCP-1 ELISA test kit, kindly provided by HBT (Uden, The Neth-
erlands). The lower detection limit of the immunoassays was 10 pg/ml.
Adhesion molecule detection assays
Supernatants from activated HUVEC were collected, and the endothelial
cells were rinsed three times with PBS supplemented with 0.9 mM CaCl2
and 0.5 mM MgCl2 (PBS/Ca/Mg), and fixed with 0.025% (w/v) glutaral-
dehyde (Serva, Heidelberg, Germany) at room temperature for 15 min. The
fixed cells were rinsed three times with PBS/Ca/Mg, then incubated with
1% (w/v) BSA in PBS and analyzed for cell surface expression of E-
selectin, ICAM-1, and VCAM-1. These proteins were detected, respec-
tively, by 1 h incubation with biotinylated mAb ENA-2 (26), biotinylated
mAb HM-1 (27), or mAb 1G11, the latter a kind gift from Dr. D. O.
Haskard (Department of Rheumatology, Hammersmith Hospital, London,
U.K.) (28, 29). After three washings in 0.1% (w/v) BSA in PBS, the pri-
mary Abs were detected by peroxidase-labeled streptavidin (Zymed) or
peroxidase-conjugated goat anti-mouse IgG (Jackson, West Grove, PA) by
incubation for 1 h. As negative controls, the primary Abs were replaced by
0.1% BSA in PBS or by a nonrelevant antiserum. All Abs were diluted in
0.1% BSA in PBS. Peroxidase activity was determined as described above.
To correct for differences in cell numbers between individual wells, we
routinely performed a crystal violet staining in each well, after the ELISA
test. The culture plates were rinsed in distilled water and dried overnight.
Cell nuclei were stained with 5 mM crystal violet (50 ml/well; Merck
(Darmstadt, Germany) for 30 min. After rinsing in distilled water, the
crystal violet was solubilized from the nuclei with 96% ethanol by shaking
the plates for 10 min. Absorbance was measured by photospectrometry at
590 nm.
Adhesion assay
HUVECs (5 3 104 cells/well) were plated into fibronectin-coated 24-well
tissue culture plates (Costar). When monolayers were confluent, the cells
were rinsed thoroughly in RPMI 1640 and stimulated with 160 nM factor
Xa or 0.2 nM TNF in serum-free culture medium. After 7 h of incubation,
the cells were washed once with medium and incubated for 15 min at 37°C
with PMNs (4 3 105 cells/well) in a total volume of 500 ml/well. At the
end of the incubation period, the nonadherent cells were removed by wash-
ing twice with 0.1% BSA in RPMI 1640. Adherent cells were lysed with
200 ml of 0.5% Triton X-100 (Sigma) by shaking for 10 min. Myeloper-
oxidase activity of the adherent cells was measured by adding 200 ml of
0.04% tetramethylbenzidine. The reaction was terminated after 20 min by
adding 50 ml of 5 M H2SO4, and the absorbance was determined at 450 nm.
A standard curve was prepared by dilution of a sample of known PMN
content.
Statistical analysis
Data in the figures are presented as mean 6 SEM of one representative
experiment. Differences between the various treatments were tested by Stu-
dent’s t test and were considered statistically significant at p , 0.05.
Results
Factor Xa induces cytokine production
Treatment of HUVEC with bovine factor Xa resulted in a signif-
icantly increased release of the cytokines IL-6, IL-8, and MCP-1
into the culture supernatants. Cytokine production was detectable
at 5 nM factor Xa and increased with the concentration of factor
Xa (Fig. 1, A–C). Similar concentration-response curves of cyto-
kine production were obtained with human factor Xa (data not
shown). While the amount of IL-8 released under the influence of
80 nM factor Xa was almost equal to that released by 0.1 nM
TNF-a, the production of IL-6 and MCP-1 was about two to three
times lower in comparison with TNF-a (data not shown). In the
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next series of experiments, time-response curves of IL-8 produc-
tion by factor Xa (10 and 80 nM) or TNF-a (0.1 nM) were deter-
mined (Fig. 2A). Elevated IL-8 levels became apparent as early as
4 h after stimulation with 10 or 80 nM factor Xa, and the levels
continued to increase up to 24 h. The kinetics of TNF-a-induced
IL-8 production follow the same pattern. After 24 h of stimulation
with 80 nM factor Xa or 0.1 nM TNF-a, the levels of IL-8 in the
culture media were 75 and 94 ng/ml, respectively. In addition, no
disparity was observed between the kinetics of factor Xa- and
TNF-a-induced production of IL-6 and MCP-1 (data not shown).
Since under physiologic conditions factor Xa becomes inhibited
by protease inhibitors, we considered it important to investigate
cytokine release also after short term exposures. Knowing that
thrombin leads to induction of IL-8 and MCP-1 transcripts within
2 to 3 h (30, 31), we incubated HUVEC with factor Xa (40 nM) or
thrombin (10 nM) for 30 or 120 min. Subsequently, the cells
were maintained in factor Xa- or thrombin-free culture medium
up to 20 h, after which time IL-8 and IL- 6 levels in the culture
supernatants were assayed (Fig. 2B). IL-8 release was already in-
creased by 30% after 30 min and by 100% after 120 min of stim-
ulation (Fig. 2B). Enhanced IL-6 levels (twofold increase) became
apparent after 120 min of stimulation with factor Xa (data not
shown). Thrombin (10 nM) stimulation during 30 min evoked a
threefold increase in IL-8 release (Fig. 2B). Measurements of the
amount of active factor Xa showed that, after 120 min of incuba-
tion, 60% of its initial concentration could be recovered from the
culture supernatant.
Factor Xa induces expression of adhesion molecules
Effects on expression of the adhesion molecules E-selectin,
ICAM-1, and VCAM-1 were studied in long term incubations with
5 to 160 nM factor Xa. Surface expression of E-selectin, which is
not constitutively present on resting HUVEC, was measured after
5 h, whereas ICAM-1 and VCAM-1 expression were evaluated
after 20 h incubation. Expression of E-selectin became apparent
after stimulation with 5 to 40 nM factor Xa (Fig. 3A). It increased
upon more prolonged exposure (8–12 h) to factor Xa, but then
decreased again after 24 h of stimulation (Fig. 4). Incubation with
factor Xa (40–160 nM) during 20 h resulted in a threefold in-
creased expression of both ICAM-1 and VCAM-1 (Fig. 3, B and C).
The property of the adhesion molecules to mediate leukocyte
adhesion to endothelial cells was evaluated by an adhesion assay
using PMNs. Binding of PMNs to factor Xa treated endothelial
cells was significantly up-regulated as compared with binding to
untreated cells (Fig. 5), indicating the significance and bioactivity
of the detected adhesion molecule expression.
Factor Xa exerts direct proinflammatory effects on endothelial
cells
We used several approaches to identify factor Xa as the actually
responsible inducer of cytokine production and adhesion molecule
expression. First, control experiments using the Limulus amebo-
cyte lysate assay showed that ,10 pg/ml LPS was present in the
factor Xa preparations, in accordance with the observation that
after heating (100°C, 5 min), factor Xa failed to induce IL-8 pro-
duction (Table I). Moreover, an LPS-induced response could be
excluded, since addition of polymyxin B (10 mg/ml) to the culture
medium did not affect the factor Xa-induced E-selectin expression,
while LPS-mediated E-selectin expression was inhibited (Table
II). To exclude a role of contaminating thrombin, the previous
FIGURE 1. Concentration-dependent release of the proinflammatory
cytokines IL-6, IL-8, and MCP-1 by factor Xa. HUVEC grown to conflu-
ence were incubated in serum-free medium with factor Xa (5–80 nM) for
20 h. Supernatants were collected and assayed for IL-6 (A), IL-8 (B), or
MCP-1 (C) content by ELISA. Data represent mean values 6 SEM of
quadruplicate determinations from a representative experiment. Four sets
of independent experiments were performed. Error bars were omitted if
they fell within the symbol. Asterisks indicate a statistically significant
difference compared with controls (p , 0.01).
FIGURE 2. Time-dependent induction of IL-8 production by factor Xa
and TNF-a. A, Confluent monolayers of HUVEC were stimulated with
factor Xa (10 and 80 nM) or TNF-a (0.1 nM), and supernatants taken at 4,
8, 12, or 24 h were assayed for IL-8 content by ELISA. Data are expressed
as mean values 6 SEM of quadruplicate determinations from one exper-
iment; at least four experiments were performed. Error bars were omitted
if they fell within the symbol. B, HUVEC were exposed to medium alone
(control), factor Xa (40 nM), or thrombin (10 nM) during a short term
period of 30 or 120 min. Supernatants were collected, and the cells were
washed and cultured in serum-free medium without proteases for up to
20 h. Values are mean 6 SEM of quadruplicate determinations. Asterisks
indicate a statistically significant difference with control cultures (p , 0.01).
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experiments had been conducted in serum-free medium to prevent
the possibility of thrombin formation from prothrombin. That
thrombin was completely absent was confirmed by the inability of
the culture supernatants to cleave the chromogenic thrombin sub-
strate S2238 (data not shown). Furthermore, addition of the throm-
bin-specific inhibitor hirudin had no effect on the factor Xa-in-
duced production of IL-6, IL-8, and MCP-1 nor on the expression
of E-selectin, ICAM-1, and VCAM-1, regardless of the factor Xa
concentration used, while thrombin-induced effects were impaired
(Tables I and II). ATIII, a physiologic inhibitor of both thrombin
and factor Xa, completely abolished the factor Xa-induced cyto-
kine production or adhesion molecule expression (Tables I and II).
Neither ATIII nor hirudin inhibited TNF-a-stimulated IL-8 pro-
duction or E-selectin expression (Tables I and II).
Moreover, the direct proinflammatory effects of factor Xa on
HUVEC were confirmed using the IL-1Ra and a TNF-neutralizing
Ab, 61E71, to rule out an intermediate role of IL-1a or TNF-a.
Neither IL-1Ra nor the anti-TNF mAb affected the expression of
E-selectin (Fig. 6) or the production of IL-8 (data not shown) in-
duced by factor Xa. IL-1a- and TNF-a-mediated effects on E-
selectin expression and IL-8 production were completely inhibited
by IL-1Ra and the anti-TNF mAb, respectively.
FIGURE 3. Factor Xa-induced expression of adhesion molecules. Ef-
fects are shown of different concentrations factor Xa (5–160 nM) on ex-
pression of E-selectin (A), ICAM-1 (B), or VCAM-1 (C). After 5 h (E-
selectin) or 20 h (ICAM-1 and VCAM-1) of stimulation, supernatants were
collected and the cells were fixed with glutaraldehyde. Adhesion molecule
expression was examined as indicated in Materials and Methods. Data are
the mean 6 SEM of quadruplicate assays and are the results of a repre-
sentative experiment. Four experiments were performed with different cell
preparations. Asterisks indicate a statistically significant difference com-
pared with controls (p, p , 0.05; pp, p , 0.01).
FIGURE 4. Kinetics of E-selectin expression induced by factor Xa.
HUVEC were incubated for the time intervals indicated with different con-
centrations of factor Xa (10 and 80 nM). Expression of E-selectin by un-
stimulated cells remained below the detection limit. Data are expressed as
mean 6 SEM of quadruplicate determinations. Four experiments were per-
formed with different cell preparations.
FIGURE 5. Adherence of activated PMNs to HUVEC. HUVEC were
incubated for 7 h with 160 nM factor Xa or 0.1 nM TNF-a and incubated
after washing with FMLP-activated PMNs. Adherent cells were detected
using myeloperoxidase activity as indicated in Materials and Methods. The
results are expressed as the percentage increase of PMN adherence com-
pared with untreated HUVEC (mean 6 SEM of five determinations). As-
terisks indicate a significant increase compared with untreated HUVEC (p,
p , 0.01; pp, p , 0.001).
Table I. Specificity of factor Xa-mediated IL-8 productiona
Activation Conditions IL-8 (ng/ml)
Expt. 1
Control 6.91 6 0.32
fXa, 5 nM 16.57 6 0.29
fXa, 80 nM 42.50 6 1.06
fXa, 5 nM 1 ATIII 7.59 6 0.37
fXa, 80 nM 1 ATIII 8.17 6 0.47
ATIII 6.61 6 0.21
Expt. 2
Control 10.81 6 2.37
fXa, 5 nM 29.99 6 2.83
fXa, 80 nM 40.67 6 1.21
fXa, 5 nM 1 hirudin 26.64 6 2.30
fXa, 80 nM 1 hirudin 41.29 6 1.47
Thrombin 43.50 6 1.66
Thrombin 1 ATIII 13.29 6 2.16
Thrombin 1 hirudin 12.91 6 0.11
TNF-a 27.26 6 0.64
TNF-a 1 ATIII 29.55 6 0.93
TNF-a 1 hirudin 24.38 6 2.24
Expt. 3
Control 1.10 6 0.06
fXa, 80 nM 9.60 6 0.52
fXa, 80 nM heated 1.56 6 0.1
a HUVEC were stimulated during various time periods with factor Xa (fXa; 5 or
80 nM), thrombin (10 nM), or TNFa (0.01 nM). Incubations contained ATIII (160
nM) or hirudin (5 U/ml), as indicated. Where indicated, factor Xa was heated at 100°C
for 5 min. Culture supernatants were collected after 20 h (Expts. 1 and 2) or after 5 h
(Expt. 3) and assayed for IL-8 content. Data represent mean values 6 SEM of qua-
druplicate determinations and are representative of at least three independent exper-
iments. In the same experiments, in addition to IL-8 the levels of MCP-1 and IL-6 in
the supernatants were also determined; results similar to those shown here were ob-
tained for IL-8 production.
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Importance of the catalytic and gla domains of factor Xa for
stimulation of cytokine production
To obtain information about which characteristic features of factor
Xa, such as its enzymatic activity and its Ca21-membrane binding
properties, are neccesary for the observed proinflammatory re-
sponses, we used two modified forms of factor Xa. First, irrevers-
ibly inactivated factor Xa was prepared by treatment with the ac-
tive site inhibitor DEGR-chloromethyl ketone. The loss of
enzymatic activity was verified by measuring the amidolytic ac-
tivity of Pefachrome Xa, as described (19). Second, factor Xa lack-
ing the gla residues responsible for Ca21-dependent binding (2)
was tested in our HUVEC system. Both of the modified forms of
factor Xa failed to induce IL-8 production (Fig. 7). Accordingly,
both the active site and the gla domain seem to be required for this
cytokine production.
Studies on involvement of EPR-1 in factor Xa-induced cytokine
release
To address the question whether EPR-1 is involved in the factor
Xa-induced cytokine production by HUVEC, we used several ap-
proaches. We applied the anti-EPR-1 mAbs B6 (data not shown)
and 9D4 (5, 10), described to inhibit the binding of 125I-labeled
factor Xa to HUVEC and EPR-1 CHO-transfected cells in our
assays. No inhibitory effect of 9D4, in a concentration range from
25 to 100 g/ml, was found on the IL-8 production induced by
human or bovine factor Xa (5–40 nM; Fig. 8A). In addition, in
peptide competition experiments, neither the factor X peptide
Leu83-Leu88 (0.25 -1 mM) (Fig. 8B) nor the EPR-1 derived peptide
AG1 (data not shown) were effective in inhibiting factor Xa-de-
pendent IL-8 production. Neither the EPR-1 mAbs nor the differ-
ent peptides by themselves caused stimulation of IL-8 production.
Discussion
It is generally recognized that activation of coagulation is closely
linked to immune and inflammatory responses in vivo. Although
inflammation constitutes a major trigger by which the hemostatic
anticoagulant properties of endothelium can be modified into a
procoagulant state resulting in pathologic conditions such as dis-
seminated intravascular coagulation (32, 33), it is appreciated that
the coagulation process itself is also able to induce inflammatory
responses (34, 35). Several studies have shown that anticoagulant
treatment not only diminishes activation of coagulation but also
inhibits inflammation, indicating the extensive interplay between
these processes. For instance, Carr et al. showed that tissue factor
FIGURE 6. Lack of involvement of IL-1 or TNF-a on factor Xa-in-
duced E-selectin expression. HUVEC were incubated in the absence of
presence of IL-1Ra (10 mg/ml; A) or 61E71 (10 mg/ml; B) with factor Xa
(80 nM), IL-1a (1 U/ml), or TNF-a (0.1 nM). After a 7-h incubation
period, cells were fixed with glutaraldehyde and assayed for E-selectin
expression. Data are represented as the mean 6 SEM of quadruplicate
determinations and are the results of one representative experiment. Three
experiments were performed with different cell preparations. p, Statistically
significant difference compared with controls (p , 0.01); #, statistically
significant difference compared with cultures without IL-1Ra or 61E71
(p , 0.01).
FIGURE 7. Structural requirements of factor Xa for cytokine release.
HUVEC were incubated with either 40 nM factor Xa, factor Xa lacking the
amino-terminal gla residues (factor Xa-gla), or factor Xa catalytically in-
activated by DEGR-chloromethyl ketone treatment (factor Xa-DEGR).
Culture supernatants were collected after 20 h and assayed for IL-8 content.
Values are the mean 6 SEM of quadruplicate determinations. Error bars
were omitted if they fell within the symbol. p, Statistically significant dif-
ference compared with controls (p , 0.001); #, statistically significant
difference compared with factor Xa treatment (p , 0.001).
Table II. Specificity of factor Xa-mediated E-selectin expressiona
Activation Conditions E-selectin (OD 450)
Expt. 1
Control 0.12 6 0.02
fXa, 10 nM 0.33 6 0.01
fXa, 80 nM 0.52 6 0.02
fXa, 10 nM 1 ATIII 0.12 6 0.02
fXa, 80 nM 1 ATIII 0.12 6 0.01
ATIII 0.11 6 0.01
Thrombin 0.75 6 0.03
Thrombin 1 ATIII 0.11 6 0.01
fXa, 10 nM 1 hirudin 0.36 6 0.04
fXa, 80 nM 1 hirudin 0.49 6 0.01
Hirudin 0.13 6 0.01
Thrombin 1 hirudin 0.12 6 0.00
TNF-a 1.03 6 0.02
TNF-a 1 ATIII 0.97 6 0.02
TNF-a 1 hirudin 0.94 6 0.02
Expt. 2
Control 0.13 6 0.01
Control 1 polymyxin B 0.13 6 0.01
fXa, 40 nM 0.72 6 0.07
fXa, 40 nM 1 polymyxin B 0.71 6 0.08
LPS 0.47 6 0.06
LPS 1 polymyxin B 0.15 6 0.03
a HUVEC were stimulated during various time periods with factor Xa (fXa; 5–80
nM), thrombin (10 nM), TNF-a (0.1 nM), or LPS (0.1 mg/ml). Incubations contained
ATIII (160 nM), hirudin (5 U/ml), or polymyxin (10 mg/ml), as indicated. Cells were
fixed after 4 h and examined for E-selectin expression. Data represent mean values 6
SEM of quadruplicate determinaitons and are representative of at least three inde-
pendent experiments. In similar experiments, expression levels of ICAM-1 and
VACM-1 were determined after 20-h incubations. These measurements gave similar
results as given here for E-selectin expression.
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pathway inhibitor reduced the inflammatory response, as measured
by plasma IL-6 levels, in a baboon model of septic shock (36).
Furthermore, Hisama et al. described that ischemia-reperfusion-
induced inflammatory responses, characterized by cytokine pro-
duction and tissue accumulation of neutrophils, in a rat liver
ischemia-reperfusion model, were significantly reduced by antico-
agulant treatment, suggesting a role of microthrombus formation in
the generation of inflammation after ischemia-reperfusion (37).
Recently, it has become evident that, in addition to their critical
role in coagulation and fibrinolytic processes, plasma serine pro-
teases trigger a diversity of cellular responses, including inflam-
matory reactions. For instance, it is well known that thrombin acts
as a potent proinflammatory agonist of endothelial cells. Thrombin
not only increases vascular permeability, but also stimulates at-
traction and binding of neutrophils and monocytes to the endothe-
lium by induction of cytokine release and expression of adhesion
molecules, such as P- and E-selectin (30, 31, 38–41). Also, factor
Xa has been shown to mediate a variety of biologic effects in
addition to its function as a pivotal enzyme in coagulation. Several
authors have described a role for factor Xa in mitogenesis and in
lymphocyte activation (4–7). There is also evidence that factor Xa
can trigger inflammatory processes (8). Injection of factor Xa in
the rat paw resulted in inflammation, as estimated by edema for-
mation, through binding and activation of mast cells. Many of
these biologic effects may be mediated through the interaction of
factor Xa with a specific membrane receptor, EPR-1. The present
study is the first to demonstrate that factor Xa is an effective in-
ducer of a proinflammatory response in endothelial cells. Our data
show that, in HUVEC, factor Xa ranging from 5 nM and higher
induce time- and concentration-dependent production of the cyto-
kine IL-6 and the chemokines IL-8 and MCP-1 and stimulate ex-
pression of the adhesion molecules E-selectin, ICAM-1, and
VCAM-1. Moreover, the factor Xa-induced adhesion molecule ex-
pression accommodated neutrophil adherence to the cells. The
physiologic relevance of the proinflammatory actions of factor Xa
on endothelial cells remains to be established. However, short term
exposure (120 min) of HUVEC to factor Xa already stimulates
considerable IL-8 and IL-6 production, and prolonged exposure
leads to higher levels. In vivo, factor Xa activity is down-regulated
by protease inhibitors; despite this fact, concentrations of 10 nM
and higher can be reached in plasma (42). Even higher concentra-
tions of factor Xa may be present locally, since factor Xa is gen-
erated on cells by tissue factor/factor VIIa and factor VIIIa/IXa
and are stabilized on their phospholipid surface by factor Va,
which may lead to protracted and intense factor Xa activity on
these cells. Also, factor Xa may act synergistically with other ac-
tivators, a concept that is the focus of current investigations.
The effects of factor Xa closely resemble the well-known in-
flammatory actions of thrombin. The effects were not mediated by
contamination with or formation of thrombin, but instead were
direct consequences of factor Xa interaction with endothelial cells,
because: 1) thrombin amidolytic activity was not detected after
exposure of the cells to factor Xa; 2) the specific thrombin inhib-
itor hirudin was unable to block factor Xa-induced cytokine pro-
duction and adhesion molecule expression; whereas 3) the com-
bined factor Xa and thrombin inhibitor antithrombin III blocked all
of these responses.
Furthermore, we could exclude the possibility that other activa-
tors, such as IL-1a and TNF-a, were involved in the observed
actions of factor Xa, since neither an IL-1Ra nor a TNF-neutral-
izing Ab affected factor Xa-induced responses.
Studies to assess the structural domains of factor Xa involved
reveal that its active site is required because treatment of factor Xa
with the chloromethyl ketone inhibitor DEGR, which alkylates the
histidine residue of the catalytic site of factor Xa, inhibits cytokine
production. This is probably not due to defective binding of factor
Xa to the cells, since Ambrosini and Altieri have shown that this
type of active site-inhibited factor Xa had normal characteristics of
binding to HUVEC (21). Our data thus support those from other
authors showing that the active site of factor Xa is required for
mitogen release by endothelial cells and for EPR-1-mediated pro-
liferation of smooth muscle cells (5, 43). Furthermore, it was
shown that the amino-terminal gla residues of factor Xa are re-
quired for induction of the proinflammatory responses in HUVEC.
This finding is in accord with the data from Gajdusek et al. who
have reported that factor Xa lacking the gla domain failed to in-
duce mitogen release by endothelial cells (43). Occupancy of a
limited number of gla residues by Ca21 leads to stabilization of a
specific conformational state of the protein and thus supports its
binding to membrane lipids and membrane-bound factor Va (44).
Although not much is yet know about the ligand requirements
to activate other factor Xa receptors, our data indicate that the
gla domain has a structural function that would support these
interactions.
Since EPR-1 is reportedly involved in various factor Xa-medi-
ated biologic events such as the increase of cytosolic-free calcium
in single adherent T cells (4), the augmentation of CD3/T cell
receptor-dependent lymphocyte proliferation (4), the costimulated
FIGURE 8. Involvement of EPR-1 in factor Xa-induced cytokine re-
lease. HUVEC were preincubated for 1 h and for 30 min, respectively, with
A, anti-EPR-1 mAb 9D4 (25 and 100 g/ml) or the control mAb CB1 or with
B, the factor X-peptide Leu83-Leu88 (0.25–1 mM) or its scrambled control
peptide. After preincubation, human factor Xa (40 nM) was added to the
cells for 24 h in A and for 12 h in B. Supernatants were collected and
assayed for IL-8 content. Values are the mean 6 SEM of quadruplicate
determinations and are representative of at least five experiments in each
situation with either bovine or human factor Xa.
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proliferation of mononuclear cells (4), and mitogenic signaling of
endothelial and smooth muscle cells (5–7), we have investigated
whether the proinflammatory responses evoked in HUVEC by fac-
tor Xa are also mediated by EPR-1. An inflammatory response, as
measured by the formation of edema (8) is mediated by the factor
X-derived peptide Leu83-Leu88, which mediates ligand binding to
EPR-1. This peptide lacks enzymatic activity, which indicates that
the active site of factor Xa was not involved in that particular
inflammatory response. In contrast, our studies clearly show that
the enzymatic activity of factor Xa is needed for the induction of
cytokine production and adhesion molecule expression by
HUVEC. Since the results of our studies indicate that EPR-1 is not
involved in factor Xa-stimulated cytokine production, the exact
biologic mechanism of factor Xa-induced proinflammatory re-
sponses in HUVEC needs to be determined.
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